Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 220 shares |
| Price | £16.5875 per share |
| Date of Transaction | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the re-investment of dividends paid to shareholders on July 14, 2016, by Mrs. D. Connor, a PCA of Mr. R. G. Connor (President, Global Manufacturing & Supply).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of a specific share acquisition event.
Investor Verification Points
- Verify the identity of the PCA (Mrs. D. Connor) and her relationship to the PDMR (Mr. R. G. Connor).
- Confirm the transaction date (July 14, 2016) aligns with the dividend payment date.
- Note that this filing does not reflect broader company performance or strategic shifts.